Category: Ribometrix

Genentech, a member of the Roche Group, will apply Ribometrix’s discovery platform to discover, develop, and commercialize small molecule drug candidates against RNA targets, through a collaboration that could generate more than $1 billion for the Durham, NC-based developer of RNA-based small molecule therapeutics.